Please assess the completion status of the following clinical trial:

Trial Title: Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females, between 18 and 55 years of age, inclusive~* Females must be nonpregnant, nonlactating, and either postmenopausal or surgically sterile or practicing an effective method of birth control~* Males must be surgically sterile, abstinent, or practicing an effective method of birth control~* BMI between 20 and 34.9 kg/m2, inclusive~Exclusion Criteria:~* Allergy to lidocaine, midazolam, or other anesthetics/sedatives of similar classes~* Physician-diagnosed migraine headaches within 3 years~* Previous enrollment in a TR-701 or TR-701 FA trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- healthy volunteer (Type: EXPERIMENTAL): healthy volunteers

Based on this trial design, predict the completion outcome and termination type (if applicable).